At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 78 enrolled

Drug / intervention

AUT00063 +1 moredrug

Likely dose

AUT00063 600 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02345031

NCT02345031Phase 2Completed

A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss [CLARITY-1 Study]

Autifony Therapeutics Limited·interventional·Posted Jan 26, 2015·Updated Aug 9, 2018

In Brief

A Phase 2 clinical trial evaluating AUT00063 and Placebo for Age-Related Hearing Loss. Completed, enrolled 78 participants across 13 sites.

This study aims to demonstrate that the investigational drug AUT00063 is effective and safe in the treatment of age-related hearing loss.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesUnited States

Collaborators--

Phase 2CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartJan 2015

First PostedJan 2015

Primary CompletionMay 2016

Study CompletionJun 2016

TodayJul 2026

First PostedJan 26, 2015

Enrollment StartJan 1, 2015

Primary CompletionMay 1, 2016

Study CompletionJun 1, 2016

TodayJul 2, 2026

Enrollment to primary: 1.3 yearsPosted 11.4 years ago

AUT00063drug

600 mg, orally, once a day, for 4 weeks

Placebodrug

orally, once a day, for 4 weeks